11.01.2019 • NewsElaine BurridgeIneos OxideWilmar

Ineos Oxide Closes Wilmar Purchase

Ineos Oxide Closes Wilmar Purchase (c) Ineos
Ineos Oxide Closes Wilmar Purchase (c) Ineos

In its first acquisition of 2019, Ineos Oxide has completed the purchase of Wilmar’s ethoxylation plant in Lavéra, France.

Graham Beesley, Ineos Oxide’s CEO, commented: “This acquisition comes at an opportune moment for Ineos’s Lavéra ethylene oxide (EO) activities following the recent decision to invest in the Lavéra site.”

The company said last September it planned to spend €200 million on upgrading its European EO plants to meet increased demand, of which €50 million was to be spent at Lavéra in southern France with €150 million going to expand production and storage at Zwijndrecht in Belgium. Ineos expects EO capacity at Lavéra to ultimately reach 270,000 t/y.

Nathalie Haeberli, business manager alkoxylation, added that Ineos Oxide now operates alkoxylation assets on three integrated sites. She said: “We look forward to adding this capacity to our network, that together with our upcoming expansion in Zwijndrecht, Antwerp, Belgium, increases our offering to the European market.”

The acquisition includes the site’s production infrastructure and employees, but Wilmar's commercial portfolio is excluded from the deal.

As part of the transaction, Ineos and Wilmar Europe Trading have entered into a toll manufacturing agreement, which guarantees Wilmar a long-term supply of surfactants from Ineos’s European network.

Wilmar said it now has access to five locations for ethoxylation in northwestern and southern Europe and will continue expanding its activities in European surfactants markets around its natural fatty alcohol plant which it owns and operates in Rozenburg, the Netherlands.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.